2. Market Trends and Outlook 2.1 Key economic indicators-Singapore 2.2 Production index 2.3 Export turnover 2.4 Value addition 2.5 Human resources 2.6 Cost of operation 2.7 Capital expenditure 2.8 Net value of fixed assets 2.9 Market outlook
3. Leading Players and Comparative Matrix 3.1 Leading Players 3.1.1 Star Pharmaceuticals Limited (Star) 3.1.2 Haw Par Corp Limited (Haw Par) 3.1.3 Pharmesis International Limited (Pharmesis) 3.2 Comparative matrix 3.3 SWOT analysis
4. Tables and Charts Table 1: Key highlights of good manufacturing practice standards Table 2: Key government initiatives Table 3: Key financial ratios of leading players FY14 Table 4: Comparison of half-yearly results of leading players 1H15
Chart 1: Top exporters of medicinal and pharmaceutical Products Chart 2: Total sales output achieved by pharmaceuticals sector Chart 3: Domestic sales of pharmaceuticals in Singapore in FY13 Chart 4: Cost of business start-up procedures-2014 Chart 5: Singapore quarterly GDP growth rate-Y/Y change Chart 6: Quarterly exports from Singapore Chart 7: Annual trade balance of Singapore Chart 8: Annual fiscal balance of Singapore government Chart 9: USD/SGD exchange rates-Monthly average Chart 10: Core inflation in Singapore Chart 11: Index of industrial production Chart 12: Growth trend in manufacturing output Chart 13: Share of different sectors in non-oil domestic exports of Singapore Chart 14: Pharmaceutical exports Chart 15: Value addition done by various sectors Chart 16: Annual value added by pharmaceutical sector Chart 17: Number of workers employed in pharmaceutical sector Chart 18: Average annual remuneration per worker Chart 19: Breakup of cost of operation in pharmaceutical sector Chart 20: Operating margins in different manufacturing sectors Chart 21: Breakup of capex done by the manufacturing industries Chart 22: Annual capital expenditure in pharmaceutical sector Chart 23: Breakup of total net value of fixed assets by industries Chart 24: Net value of fixed assets-Annual Chart 25: Business outlook in terms of net weighted balance for 2HFY15 Chart 26: Segmental revenues of Star Chart 27: Net sales of Star Chart 28: Profit margins of Star Chart 29 Segmental revenues of Haw Par Chart 30: Net sales of Haw Par Chart 31: Profit margins of Haw Par Chart 32: Segmental revenues of Pharmesis Chart 33: Net sales of Pharmesis Chart 34: Profit margins of Pharmesis
Singapore Pharmaceutical Industry Report - 2015 Description
This report profiles Singapore’s pharmaceutical industry, discussing market trends through 2014 and outlook for 2015 and beyond. The report also highlights leading players in the sector including Star Pharmaceuticals Limited, Haw Par Corp Limited and Pharmesis International Limited.
Singapore has successfully established a strong healthcare infrastructure ranked amongst the best in the world. The country has also become a major pharmaceutical trading hub of Southeast Asia. It is for this reason that more than 30 leading pharmaceutical and biomedical science companies have established regional headquarters in Singapore. The country is also the preferred site for the manufacturing base of leading multinational pharmaceutical companies.
Pharmaceutical manufacturing has been one of the major contributors to the overall growth of the domestic manufacturing industry in recent years. A substantive portion of total pharmaceuticals output were re-exported Singapore. But, the value of output and exports has declined during the last two years owing to uncertain global economic environment.
The outlook for Singapore pharmaceuticals is positive owing to the availability of skilled manpower, the presence of leading research institutions, a proactive government, relaxed regulatory environment, intellectual property protection and state of the art infrastructure. In addition, its strategic geographic location is bound to attract multinational companies which will establish their base in Singapore in the years to come.
Total manufacturing output of the pharmaceuticals sector grew at a CAGR of 6% during 2009-12. However, it saw a steep decline in 2013, followed by another decline in 2014.
The domestic manufacturing sector had a capital expenditure of SGD 14.5bn in 2013. Pharmaceuticals accounted for 2% of the total capital expenditure. Most of the investment made was for the establishment of research and development laboratories.
Pharmaceutical exports accounted for 3% of the total non-oil domestic exports in 2014. Pharmaceutical exports grew at a CAGR of 13% during 2008-12. It contracted by 13% in FY13, but revived slightly in FY14 growing by 4% y/y.